title: New and Emerging Evidence on the Use of Second-Generation Direct Acting Antivirals for the Treatment of Hepatitis C Virus in Renal Impairment.
abstract: Due to the intimate relationship between liver and kidney disease in hepatitis C virus (HCV) infection, treatment options for HCV-positive patients at any stage of chronic kidney disease (CKD) are essential. The availability of second-generation, direct-acting antiviral (DAA) combinations has allowed for the advent of interferon-sparing treatment regimens with shorter durations and minimal side effects. While many of the second-generation DAAs are principally metabolized by the hepatic system, dosing in severe renal impairment (creatinine clearance [CrCl] <30 mL/min) or dialysis has remained questionable due to limited experience. New evidence regarding the use of these agents in renal impairment continues to become available, as real-world experience with these treatment regimens is reported. Simeprevir, ledipasvir, paritaprevir, ombitasvir, dasabuvir, and daclatasvir have data to suggest safety in end-stage renal disease. While safety and efficacy with sofosbuvir remains uncertain, data are now available to support utilizing a dose adjustment when glomerular filtration rates are <30 mL/min. Upcoming regimens grazoprevir/elbasvir and daclatasvir/asunaprevir/beclavubir may provide further options for patients with advanced kidney disease, and ongoing studies will continue to provide guidance for this unique patient population. This article will review the currently available literature, including the newest emerging evidence, on the use of second-generation DAAs in CKD stages 3 to 5 and dialysis.
authors.affiliation: 1 Pharmacy Practice Department, Touro College of Pharmacy, New York, NY, USA.
authors.forename: Maria A
authors.initials: MA
authors.lastname: Sorbera
authors.affiliation: 1 Pharmacy Practice Department, Touro College of Pharmacy, New York, NY, USA.
authors.forename: Michelle L
authors.initials: ML
authors.lastname: Friedman
authors.affiliation: 1 Pharmacy Practice Department, Touro College of Pharmacy, New York, NY, USA.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Cope
mesh_terms: D000577:Amides; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002219:Carbamates; D003521:Cyclopropanes; D016174:Hepacivirus / Q000187:drug effects*; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D011810:Quinoxalines / Q000494:pharmacology / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D013449:Sulfonamides; D016896:Treatment Outcome; D047029:Lactams, Macrocyclic
chemical_list: D000577:Amides; D000998:Antiviral Agents; D002219:Carbamates; D003521:Cyclopropanes; D011810:Quinoxalines; D013449:Sulfonamides; C578009:grazoprevir; D047029:Lactams, Macrocyclic
keywords: chronic kidney disease; dialysis; direct acting antiviral agents; hepatitis C; renal disease